Catalyst Pharmaceuticals Stock Today
| CPRX Stock | USD 23.62 0.68 2.96% |
PerformanceGood
| Odds Of DistressLow
|
Catalyst Pharmaceuticals is trading at 23.62 as of the 12th of December 2025; that is 2.96 percent increase since the beginning of the trading day. The stock's open price was 22.94. Catalyst Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 13th of September 2025 and ending today, the 12th of December 2025. Click here to learn more.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. The company has 122.91 M outstanding shares of which 7.94 M shares are currently shorted by private and institutional investors with about 5.77 trading days to cover. More on Catalyst Pharmaceuticals
Moving together with Catalyst Stock
Moving against Catalyst Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Catalyst Stock Highlights
| CEO President | Richard MBA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, SP Small-Cap 600, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Catalyst Pharmaceuticals (CPRX) is traded on NASDAQ Exchange in USA and employs 181 people. Catalyst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.82 B. Catalyst Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 122.91 M outstanding shares of which 7.94 M shares are currently shorted by private and institutional investors with about 5.77 trading days to cover.
Catalyst Pharmaceuticals currently holds about 220.79 M in cash with 239.81 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.15.
Check Catalyst Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCatalyst Pharmaceuticals holds a total of 122.91 Million outstanding shares. The majority of Catalyst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalyst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalyst Pharmaceuticals. Please pay attention to any change in the institutional holdings of Catalyst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Catalyst Ownership Details
Catalyst Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Catalyst Pharmaceuticals market risk premium is the additional return an investor will receive from holding Catalyst Pharmaceuticals long position in a well-diversified portfolio.
| Mean Deviation | 1.47 | |||
| Semi Deviation | 1.48 | |||
| Standard Deviation | 2.01 | |||
| Variance | 4.03 |
Catalyst Stock Against Markets
Catalyst Pharmaceuticals Corporate Management
| Philip Schwartz | Co Sec | Profile | |
| CMA CPA | VP, Officer | Profile | |
| Pete Sr | Vice Sales | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Stanley MD | Senior Discovery | Profile | |
| Philip Esq | Corporate Secretary | Profile |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.